Gilead Sciences Inc (GILD): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Gilead ( GILD) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 0.7%. By the end of trading, Gilead fell $1.34 (-1.9%) to $70.08 on average volume. Throughout the day, 11,731,483 shares of Gilead exchanged hands as compared to its average daily volume of 9,829,800 shares. The stock ranged in price between $69.04-$71.74 after having opened the day at $71.72 as compared to the previous trading day's close of $71.42. Other companies within the Drugs industry that declined today were: Targacept ( TRGT), down 34.3%, Rockwell Medical ( RMTI), down 19.8%, Enzymotec ( ENZY), down 13.2% and Aoxing Pharmaceutical Company ( AXN), down 10.3%.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $109.5 billion and is part of the health care sector. The company has a P/E ratio of 39.2, above the S&P 500 P/E ratio of 17.7. Shares are up 94.5% year to date as of the close of trading on Monday. Currently there are 16 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the positive front, Idenix Pharmaceuticals ( IDIX), up 17.8%, Idera Pharmaceuticals ( IDRA), up 15.1%, Puma Biotechnology ( PBYI), up 12.0% and Karyopharm Therapeutics ( KPTI), up 11.9% , were all gainers within the drugs industry with Vertex Pharmaceuticals ( VRTX) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%